1. Impact of comorbidities and inflammatory markers on mortality of COVID-19 patients
- Author
-
Azmat Karim, Mohammad Shameem, Anjana Talwar, and Deepak Talwar
- Subjects
chronic kidney disease ,comorbidity ,covid-19 ,inflammatory markers ,tuberculosis ,Diseases of the respiratory system ,RC705-779 - Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes coronavirus disease 2019 (COVID-19) is a serious global health concern. The severity of the disease can be determined by serologic indicators such as C-reactive protein, lactate dehydrogenase, D-dimer, ferritin, and interleukin-6. (IL-6). Patients with preexisting conditions such as respiratory, cardiovascular, and pulmonary disease could be at risk of adverse outcomes. It is crucial to provide adequate medical care to manage these patients and increase their chances of survival. Aim: The study examined the impact of comorbidity and inflammatory markers on the severity and mortality of hospitalised COVID-19 patients. Materials and Methods: This retrospective study included 101 COVID-19 patients who had comorbidities and were hospitalised from April 2021 to April 2022. Results: Patients with a severe COVID-19 infection could be anticipated to have higher levels of inflammatory markers in their blood. Patients with chronic kidney and coronary artery disease have a worse prognosis than those with other comorbidities (P value
- Published
- 2024
- Full Text
- View/download PDF